Prevacid | Lansoprazole Capsule, Delayed Release Breastfeeding
For most of the drugs advantages of taking medications overweighs the potential risks however some drugs could be really dangerous for breastfed baby hence every medication shall be considered separately. In this page we will discuss about purpose of Prevacid | Lansoprazole Capsule, Delayed Release and its risk associated with lactation. We will also discuss the usage of Prevacid | Lansoprazole Capsule, Delayed Release and some common side effects associated with Prevacid | Lansoprazole Capsule, Delayed Release.

What is Prevacid | Lansoprazole Capsule, Delayed Release used for?


PREVACID is a proton pump inhibitor (PPI). Refer to DOSAGE and ADMINISTRATION table (below) for indications and usage. 1.1 Short-Term Treatment of Active Duodenal Ulcer PREVACID® is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer. [See Clinical Studies (14)] 1.2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: PREVACID/amoxicillin /clarithromycin PREVACID in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. [See Clinical Studies (14)] Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: PREVACID/amoxicillin PREVACID in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin package insert, MICROBIOLOGY section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. [See Clinical Studies (14)] Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers PREVACID is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months. [See Clinical Studies (14)] 1.4 Short-Term Treatment of Active Benign Gastric Ulcer PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer. [See Clinical Studies (14)] 1.5 Healing of NSAID-Associated Gastric Ulcer PREVACID is indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond 8 weeks. [See Clinical Studies (14)] 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer PREVACID is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks. [See Clinical Studies (14)] 1.7 Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD PREVACID is indicated for the treatment of heartburn and other symptoms associated with GERD. [See Clinical Studies (14)] Short-Term Treatment of Erosive Esophagitis PREVACID is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with PREVACID for 8 weeks (5-10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8-week course of PREVACID may be considered. [See Clinical Studies (14)] 1.8 Maintenance of Healing of Erosive Esophagitis (EE) PREVACID is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months. [See Clinical Studies (14)] 1.9 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome PREVACID is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. [See Clinical Studies (14)]

Is using Prevacid | Lansoprazole Capsule, Delayed Release unsafe in breastfeeding? Can there be bad consequences for baby if I use it while breastfeeding?

Prevacid | Lansoprazole Capsule, Delayed Release safe for breastfeeding
Active ingredient in Prevacid | Lansoprazole Capsule, Delayed Release is Lansoprazole and based on our analysis of Lansoprazole it appears that using Prevacid | Lansoprazole Capsule, Delayed Release is safe in breastfeeding. Below is analysis of Lansoprazole while breastfeeding.

Statement of Manufacturer/Labeler about breastfeeding usage
8.3 Nursing Mothers Lansoprazole or its metabolites are excreted in the milk of rats. It is not known whether lansoprazole is excreted in human milk. Because many drugs are excreted in human milk, because of the potential for serious adverse reactions in nursing infants from lansoprazole, and because of the potential for tumorigenicity shown for lansoprazole in rat carcinogenicity studies, a decision should be made whether to discontinue nursing or to discontinue lansoprazole, taking into account the importance of lansoprazole to the mother.

Prevacid | Lansoprazole Capsule, Delayed Release Breastfeeding Analsys


Lansoprazole while Breastfeeding

Safe

CAS Number: 103577-45-3

At latest update, relevant information on excretion into breast milk was not found. Due to a high serum-protein-binding capacity, excretion of Lansoprazole into breast milk is non-significant. Since it's neutralized by the acid pH of stomach, capsules with enteric coated granules are used. Because of this, it is thought that the small quantity of Lansoprazole that may reach the breast milk would be neutralized by infant's stomach. In addition, absorption is greatly decreased by the presence of food. Both Omeprazole and Pantoprazole pertain to the same chemical group with similar pharmacokinetics that are excreted in non-significant amount into the breast milk. Medication that has been used for treatment of newborn and premature infants. Hyperprolactinemia and galactorrhea have been reported by the use of such medication, though some authors have failed to show the same findings.


Prevacid | Lansoprazole Capsule, Delayed Release Breastfeeding Analsys - 2


Lansoprazole while Breastfeeding

CAS Number: 103577-45-3

No information is available on the use of lansoprazole during breastfeeding. However, lansoprazole has been used safely in newborn infants, so it is unlikely that the amount in breastmilk would be harmful.


Prevacid | Lansoprazole Capsule, Delayed Release and breastfeeding

What should I do if I am breastfeeding mother and I am already exposed to Prevacid | Lansoprazole Capsule, Delayed Release?

Prevacid | Lansoprazole Capsule, Delayed Release is safe in breastfeeding and should not create any health problem for your baby but in case you feel any health issue associated with Prevacid | Lansoprazole Capsule, Delayed Release you should contact your doctor or health care provider. Be it pregnancy or lactation you shall keep your doctor informed.


My health care provider has asked me to use Prevacid | Lansoprazole Capsule, Delayed Release, what to do?

Definitely, Prevacid | Lansoprazole Capsule, Delayed Release is safe in lactation for baby. No wonder your doctor has recommended it.


If I am using Prevacid | Lansoprazole Capsule, Delayed Release, will my baby need extra monitoring?

No extra baby monitoring required while mother is using Prevacid | Lansoprazole Capsule, Delayed Release


Who can I talk to if I have questions about usage of Prevacid | Lansoprazole Capsule, Delayed Release in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week